227 related articles for article (PubMed ID: 18398901)
1. Influence of particle size and antigen binding on effectiveness of aluminum salt adjuvants in a model lysozyme vaccine.
Clausi A; Cummiskey J; Merkley S; Carpenter JF; Braun LJ; Randolph TW
J Pharm Sci; 2008 Dec; 97(12):5252-62. PubMed ID: 18398901
[TBL] [Abstract][Full Text] [Related]
2. Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application.
Maa YF; Zhao L; Payne LG; Chen D
J Pharm Sci; 2003 Feb; 92(2):319-32. PubMed ID: 12532382
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants.
Romero Méndez IZ; Shi Y; HogenEsch H; Hem SL
Vaccine; 2007 Jan; 25(5):825-33. PubMed ID: 17014935
[TBL] [Abstract][Full Text] [Related]
4. Freeze-thaw stress of Alhydrogel ® alone is sufficient to reduce the immunogenicity of a recombinant hepatitis B vaccine containing native antigen.
Clapp T; Munks MW; Trivedi R; Kompella UB; Braun LJ
Vaccine; 2014 Jun; 32(30):3765-71. PubMed ID: 24856785
[TBL] [Abstract][Full Text] [Related]
5. A method of lyophilizing vaccines containing aluminum salts into a dry powder without causing particle aggregation or decreasing the immunogenicity following reconstitution.
Li X; Thakkar SG; Ruwona TB; Williams RO; Cui Z
J Control Release; 2015 Apr; 204():38-50. PubMed ID: 25735896
[TBL] [Abstract][Full Text] [Related]
6. The immunogenicity of thin-film freeze-dried, aluminum salt-adjuvanted vaccine when exposed to different temperatures.
Thakkar SG; Ruwona TB; Williams RO; Cui Z
Hum Vaccin Immunother; 2017 Apr; 13(4):936-946. PubMed ID: 28051903
[TBL] [Abstract][Full Text] [Related]
7. Thin-Film Freeze-Drying Is a Viable Method to Convert Vaccines Containing Aluminum Salts from Liquid to Dry Powder.
Alzhrani RF; Xu H; Moon C; Suggs LJ; Williams RO; Cui Z
Methods Mol Biol; 2021; 2183():489-498. PubMed ID: 32959262
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of aggregation of aluminum hydroxide adjuvant during freezing and drying.
Clausi AL; Merkley SA; Carpenter JF; Randolph TW
J Pharm Sci; 2008 Jun; 97(6):2049-61. PubMed ID: 17879291
[TBL] [Abstract][Full Text] [Related]
9. The impact of size on particulate vaccine adjuvants.
Shah RR; O'Hagan DT; Amiji MM; Brito LA
Nanomedicine (Lond); 2014 Dec; 9(17):2671-81. PubMed ID: 25529570
[TBL] [Abstract][Full Text] [Related]
10. Methods to Prepare Aluminum Salt-Adjuvanted Vaccines.
Thakkar SG; Cui Z
Methods Mol Biol; 2017; 1494():181-199. PubMed ID: 27718194
[TBL] [Abstract][Full Text] [Related]
11. Quantitative Analysis of Vaccine Antigen Adsorption to Aluminum Adjuvant Using an Automated High-Throughput Method.
Ahl PL; Wang SC; Chintala R; Mensch C; Smith WJ; Wenger M; Blue J
PDA J Pharm Sci Technol; 2018; 72(2):149-162. PubMed ID: 29343619
[TBL] [Abstract][Full Text] [Related]
12. Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response.
Hansen B; Sokolovska A; HogenEsch H; Hem SL
Vaccine; 2007 Sep; 25(36):6618-24. PubMed ID: 17681647
[TBL] [Abstract][Full Text] [Related]
13. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro.
Morefield GL; Sokolovska A; Jiang D; HogenEsch H; Robinson JP; Hem SL
Vaccine; 2005 Feb; 23(13):1588-95. PubMed ID: 15694511
[TBL] [Abstract][Full Text] [Related]
14. Stability of an aluminum salt-adjuvanted protein D-conjugated pneumococcal vaccine after exposure to subzero temperatures.
Fortpied J; Wauters F; Rochart C; Hermand P; Hoet B; Moniotte N; Vojtek I
Hum Vaccin Immunother; 2018 May; 14(5):1243-1250. PubMed ID: 29337646
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants.
Berthold I; Pombo ML; Wagner L; Arciniega JL
Vaccine; 2005 Mar; 23(16):1993-9. PubMed ID: 15734073
[TBL] [Abstract][Full Text] [Related]
16. Formulation, stability and immunogenicity of a trivalent pneumococcal protein vaccine formulated with aluminum salt adjuvants.
Ljutic B; Ochs M; Messham B; Ming M; Dookie A; Harper K; Ausar SF
Vaccine; 2012 Apr; 30(19):2981-8. PubMed ID: 22381074
[TBL] [Abstract][Full Text] [Related]
17. Glassy-state stabilization of a dominant negative inhibitor anthrax vaccine containing aluminum hydroxide and glycopyranoside lipid A adjuvants.
Hassett KJ; Vance DJ; Jain NK; Sahni N; Rabia LA; Cousins MC; Joshi S; Volkin DB; Middaugh CR; Mantis NJ; Carpenter JF; Randolph TW
J Pharm Sci; 2015 Feb; 104(2):627-39. PubMed ID: 25581103
[TBL] [Abstract][Full Text] [Related]
18. Influence of formulation pH and suspension state on freezing-induced agglomeration of aluminum adjuvants.
Salnikova MS; Davis H; Mensch C; Celano L; Thiriot DS
J Pharm Sci; 2012 Mar; 101(3):1050-62. PubMed ID: 22113733
[TBL] [Abstract][Full Text] [Related]
19. Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability.
Clapp T; Siebert P; Chen D; Jones Braun L
J Pharm Sci; 2011 Feb; 100(2):388-401. PubMed ID: 20740674
[TBL] [Abstract][Full Text] [Related]
20. Control of antigen-binding to aluminum adjuvants and the immune response with a novel phosphonate linker.
Lu F; Boutselis I; Borch RF; Hogenesch H
Vaccine; 2013 Sep; 31(40):4362-7. PubMed ID: 23887038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
